Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Silence Therapeutics
Biotech
Silence brings the noise to Takeda with phase 2 blood cancer win
A phase 2 trial of Silence’s divesiran hit its primary endpoint, emboldening the biotech to advance a potential challenger to Takeda’s rusfertide.
Nick Paul Taylor
Aug 10, 2026 7:31am
Pfizer RNA leader runs to Replicate—Chutes & Ladders
Dec 19, 2025 8:30am
Silence slows zerlasiran, as Hansoh leaves $1.3B biobucks collab
Feb 27, 2025 8:51am
Silence breaks down phase 1 data on blood disorder prospect
Jun 27, 2024 9:40am
Silence loses Mallinckrodt collab, wins in cardiovascular ph. 2
Mar 13, 2024 8:54am
Silence takes back 2 complement programs from Mallinckrodt
Mar 28, 2023 10:42am
